$1.08
-0.02 (-1.82%)
Cell Therapeutics, Inc. (NASDAQ:CTIC)
CAPS Rating:
The Company develops, acquires and commercializes novel treatments for cancer and focuses its research and in-licensing activities on identifying and developing new, less toxic and effective ways to treat cancer.
RSS Headlines
Fool UK